SOHO 2023 | Low predictive value of PET scans in patients with Hodgkin lymphoma treated with brentuximab vedotin

Ravand Samaeekia, MD, MS, Loma Linda University Cancer Center, Loma Linda, CA, discusses the low predictive value of interim PET assessment after two cycles of treatment with brentuximab vedotin for patients with Hodgkin lymphoma (HL). Dr Samaeekia first addresses the challenges associated with PET scans, including variability in the interpretation of results. Dr Samaeekia then talks on a retrospective study evaluating PET-adapted protocols in patients with HL treated with brentuximab vedotin-containing regimens. It was found that both patients with positive and negative PET2 scans had significantly improved outcomes, meaning that specialists did not make treatment decisions based on this scan. Dr Samaeekia concludes by commenting on the benefits of omitting the PET2 scan from PET-adapted treatment protocols for these patients. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.